Guggenheim Boosts Insulet (NASDAQ:PODD) Price Target to $145.00

Insulet (NASDAQ:PODD) had its price target boosted by Guggenheim from $100.00 to $145.00 in a research note published on Tuesday, The Fly reports. The firm currently has a positive rating on the medical instruments supplier’s stock.

A number of other analysts have also recently commented on the company. ValuEngine cut Insulet from a strong-buy rating to a buy rating in a research report on Thursday, August 1st. BTIG Research upgraded Insulet from a neutral rating to a buy rating and set a $115.00 price objective for the company in a research report on Monday, May 6th. Svb Leerink reiterated an outperform rating on shares of Insulet in a research report on Wednesday, July 10th. Northland Securities cut Insulet from an outperform rating to a market perform rating and set a $100.00 price objective for the company. in a research report on Monday, June 10th. Finally, Piper Jaffray Companies upped their price objective on Insulet from $130.00 to $160.00 and gave the company an overweight rating in a research report on Tuesday. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Insulet currently has an average rating of Buy and a consensus target price of $131.71.

Insulet stock traded up $3.73 during mid-day trading on Tuesday, reaching $149.53. 17,016 shares of the stock traded hands, compared to its average volume of 505,377. The firm has a market capitalization of $8.70 billion, a PE ratio of 2,981.80 and a beta of 1.08. The company has a quick ratio of 3.71, a current ratio of 4.36 and a debt-to-equity ratio of 2.68. Insulet has a 12-month low of $70.80 and a 12-month high of $149.67. The firm’s 50-day simple moving average is $122.00.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Monday, August 5th. The medical instruments supplier reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The firm had revenue of $177.10 million for the quarter, compared to analysts’ expectations of $163.63 million. Insulet had a net margin of 2.66% and a return on equity of 8.21%. The firm’s revenue was up 42.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.03) EPS. Equities research analysts expect that Insulet will post 0.25 EPS for the current fiscal year.

In other Insulet news, insider Shacey Petrovic sold 895 shares of the company’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $113.00, for a total value of $101,135.00. Following the completion of the sale, the insider now owns 95,559 shares in the company, valued at $10,798,167. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Charles Alpuche sold 3,900 shares of the company’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $104.78, for a total value of $408,642.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 41,894 shares of company stock valued at $4,524,025. Company insiders own 3.50% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. Stephens Investment Management Group LLC boosted its stake in shares of Insulet by 19.6% in the first quarter. Stephens Investment Management Group LLC now owns 129,239 shares of the medical instruments supplier’s stock worth $12,289,000 after acquiring an additional 21,206 shares during the period. C WorldWide Group Holding A S boosted its stake in shares of Insulet by 102.6% in the first quarter. C WorldWide Group Holding A S now owns 52,672 shares of the medical instruments supplier’s stock worth $5,009,000 after acquiring an additional 26,678 shares during the period. Oak Ridge Investments LLC boosted its stake in shares of Insulet by 4.0% in the first quarter. Oak Ridge Investments LLC now owns 119,497 shares of the medical instruments supplier’s stock worth $11,363,000 after acquiring an additional 4,648 shares during the period. First Hawaiian Bank boosted its stake in shares of Insulet by 2,758.3% in the second quarter. First Hawaiian Bank now owns 1,715 shares of the medical instruments supplier’s stock worth $205,000 after acquiring an additional 1,655 shares during the period. Finally, Pier Capital LLC boosted its stake in shares of Insulet by 10.5% in the first quarter. Pier Capital LLC now owns 86,848 shares of the medical instruments supplier’s stock worth $8,258,000 after acquiring an additional 8,230 shares during the period.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Featured Story: Why is Cost of Capital Important?

The Fly

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.